Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright

23


rd


Annual Global Investment Conference

. Details of the Company’s participation are as follows:

Conference:

H.C. Wainwright 23


rd


Annual Global Investment Conference

Dates: September 13-15, 2021
Format: Fireside chat available on-demand beginning September 13

th

at 7:00am ET
One-on-one investor meetings


About Entasis


Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting

Acinetobacter baumannii

infections), zoliflodacin (targeting

Neisseria gonorrhoeae

infections), ETX0462 (targeting multiple Gram-negative pathogens including

Pseudomonas aeruginosa

) and ETX0282CPDP (targeting

Enterobacteriaceae

infections). For more information, visit

www.entasistx.com

.


Entasis Contacts



Company:


Kyle Dow

Entasis Therapeutics

(781) 810-0114


[email protected]


Investor Relations:


Bruce Mackle

LifeSci Advisors

(929) 469-3859


[email protected]



Primary Logo